Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The **human organic anion transporter 1 (OAT1, SLC22A6)** and **human organic anion transporter 3 (OAT3, SLC22A8)** are closely related **membrane transporters** in the kidney, belonging to the solute carrier (SLC22) family[1][3][5]. Both proteins are primarily expressed at the basolateral membrane of proximal tubular cells, where they mediate the uptake of a broad spectrum of endogenous and exogenous organic anions from the blood into renal epithelial cells as the first step in renal secretion and drug elimination[1][3][5]. They operate mainly via an *organic anion–α-ketoglutarate exchange mechanism*, enabling secondary active transport of anionic drugs, toxins, and metabolic waste products[2][3][5]. OAT1/OAT3 are targets for drug-drug interactions (notably inhibition by probenecid), and play important roles in the pharmacokinetics and potential nephrotoxicity of various clinical drugs, especially antivirals (tenofovir, adefovir, cidofovir)[3][4][5]. Dysfunction or pharmacological inhibition of these transporters is implicated in altered drug disposition, toxicity, and disease states such as chronic kidney disease and uremia[3][5]. Structural studies, including recent cryo-EM data, reveal that these proteins operate through complex conformational changes characteristic of the Major Facilitator Superfamily, supporting alternating access of substrates across the membrane[4][5].
Drugs inhibiting OAT1/OAT3: Block renal secretion of target drugs/metabolites, leading to increased plasma levels (e.g., probenecid blocks secretion of uric acid and drug substrates) Drugs utilizing OAT1/OAT3 for elimination: Rely on active transport into renal tubular cells (e.g., tenofovir, adefovir), followed by excretion into urine Exchange mechanism: Secondary active transport via organic anion/dicarboxylate exchanger (primarily α-ketoglutarate)
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Human organic anion transporter 1 and Human organic anion transporter 3 (OAT1 and OAT3).